Rep. Maloney and Rep. Smith To Host A Second Autism Congressional Briefing

Rep. Carolyn Maloney (D-NY) and Rep. Christopher Smith (R-NJ) To Host A Second Autism Congressional Briefing An Update On Federal Autism Research And Treatment Initiatives

Invite the WHITE HOUSE HERE. Invite CONGRESS AND SENATE HERE.

Please urge your lawmakers to attend or send a staff member to this important autism-vaccine briefing on Capitol Hill. Tell the White House how you feel about this briefing.

If you receive a reply from your lawmakers, send an email to: kirbylecture@gmail.com We'll keep a running tally of RSVP commitments at Age of Autism.

Friday, July 17 at 9:30 AM
210 Cannon House Office Building
Independence Avenue, Washington, DC.

FREE AND OPEN TO THE PUBLIC

Rep. Carolyn Maloney (D-NY) and Rep. Christopher Smith (R-NJ) are hosting a special briefing for Members of Congress and their Staff to discuss issues related to autism research and treatment. We hope that you will attend the briefing to learn about the changing dynamics of the autism debate, as you will find many in government and science believe this debate is far from settled.

David Kirby, investigative journalist and author of The New York Times bestseller Evidence of Harm, Mercury in Vaccines and the Autism Epidemic – A Medical Controversy, will inform Members and their staff about developments regarding environmental factors in autism and the “Seven Studies to Watch” – Plus, changing ASD demographics post-thimerosal reduction.  Mr. Kirby will also be joined by Mark Blaxill, Editor-at-Large of Age of Autism, Director of the Coalition for SAFE MINDS and co-author of a forthcoming book on the roots of the autism epidemic, who will address the policy and public health implications of the autism crisis.

Among the issues to be discussed are:

1) The unanimous endorsement by the National Vaccine Advisory Committee to look at the feasibility of a large vaccinated-unvaccinated study, with autism as an outcome.

2) The NVAC endorsement of three other vaccine-autism investigations, including children with mitochondrial dysfunction, children with regressive autism, and vaccine injury as a risk factor for ASD.

3) Recent Vaccine Court decisions finding the MMR and  Hep B vaccines caused injuries that led to autism and MS.

4) The NIH Early Autism Risk Longitudinal Investigations EARLI study and the HHS/EPA National Children’s Study, both of which are looking at vaccination and mercury exposures, with autism as a possible outcome.

5) The CDC’s Centers for Autism and Developmental Disabilities Research and Epidemiology (CADDRE) Network, whose five-year goal includes studying "specific mercury exposures, including any vaccine use by the mother during pregnancy and the child's vaccine exposures after birth.”

6) Cleveland Clinic – A recent article in PLoS Online by authors from the Cleveland Clinic, Harvard and Johns Hopkins University reported that, "Large, population-based studies will be needed to identify a possible relationship of vaccination with autistic regression in persons with mitochondrial dysfunction.”

7) Recent statements by Federal health officials such as Dr. Duane Alexander, Director of the Eunice Kennedy Shriver Institute of Child Health and Human Development (NICHD), who said it is important to ask if some children are, “more susceptible to some vaccine characteristic or component than most of the population, and may develop an ASD in response,” and Dr. Anthony Fauci, Director of NIAID, who said in a US News and World report article, “If we can show that individuals of a certain genetic profile have a greater propensity for developing adverse events, we may want to screen everyone prior to vaccination."

8) The U.C. Davis M.I.N.D. Institute study which found, that the seven- to eight-fold increase in the number children born in California with autism since 1990 cannot be explained by either changes in how the condition is diagnosed or counted — and the trend shows no sign of abating. This as young adults begin to flood the social services system

10) Reports of reduced Autism Spectrum Disorder (ASD) severity among the youngest children, following reduction of thimerosal in childhood vaccines.